Skip to content
RX CJC-1295

CJC-1295 references

The original papers, the trial registry and the wider sources used throughout this file.

Follow the experiments in order

Chemistry and volunteer experiments

Jette and colleagues describe the albumin-conjugating design in rats and laboratory work. Teichman and colleagues report the healthy-adult hormone and half-life findings. Ionescu and Frohman examine the pulse pattern. Those papers carry the central argument of this site.

For a different scale of observation, Alba and colleagues studied growth in GHRH-knockout mice, while Sackmann-Sala and colleagues examined human serum proteins. I particularly value having both in the file: they show how different the experiments can be behind a single compound name.

Clinical history and wider context

The Phase 2 registry entry concerns HIV-associated visceral obesity. Henninge and colleagues’ analytical identification follows a very different question. The GHRH-analog review supplies a broader view of the class.

The retained list also includes sources on fluid retention, IGF-1 and cancer associations, FDA advisory concerns and sport prohibition. These sources have different jobs. A population association, a regulatory concern and a CJC-1295 experiment each deserve their precise description.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  7. ConjuChem Inc. A study to evaluate CJC-1295 in HIV patients with visceral obesity. ClinicalTrials.gov; 2006. NCT00267527. ↗
  8. Sigalos JT, Pastuszak AW, Allison A, et al. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. Am J Mens Health. 2017. ↗
  9. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 2011. ↗
  10. Modified GRF (1-29) — chemical and pharmacological description. Encyclopedic reference; 2024. ↗
  11. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron. J Clin Endocrinol Metab. 2002. ↗
  12. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  13. A 2024 update on growth hormone deficiency syndrome in adults: from guidelines to clinical practice. J Clin Med. 2024;13(20):6079. ↗
  14. Aagaard NK, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Horm IGF Res. 2009. ↗
  15. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal conditions. Sports Med. 2026. ↗
  16. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004. 363(9418):1346-1353 ↗
  17. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting - briefing document on growth hormone secretagogues (CJC-1295). FDA Advisory Committee Briefing Materials. 2024. ↗
  18. World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA International Standard. 2025. ↗